AGÕæÈ˹ٷ½

MicroStrategy Incorporated filed a Form 8-K on 31 Jul 2025 to furnish a press release (Exhibit 99.1) containing its financial results for the quarter ended 30 Jun 2025. The actual revenue, earnings and margin figures are not included in the filing and are therefore not deemed “filedâ€� under the Exchange Act.

Separately, under Item 8.01, the board declared a $0.80 monthly cash dividend on the Variable Rate Series A Perpetual Stretch Preferred Stock (ticker STRC). The dividend covers the accrual period beginning 29 Jul 2025—STRC’s issuance date—and will be paid on 31 Aug 2025 to shareholders of record as of 15 Aug 2025.

BioXcel Therapeutics (BTAI) filed an 8-K announcing it has submitted a pre-supplemental NDA (pre-sNDA) package to the FDA seeking to expand IGALMI’s label to cover at-home treatment of acute agitation in schizophrenia or bipolar disorders. The FDA has scheduled the pre-sNDA meeting for 20 Aug 2025; BioXcel aims to confirm alignment on data requirements and formatting before filing the full sNDA. Management also intends to reconfirm guidance from a 6 Mar 2024 Type C meeting, in which the FDA deemed the company’s development plan a reasonable path to support the proposed 120 mcg BXCL501 outpatient indication.

No financial metrics were disclosed. The filing consists primarily of regulatory updates and forward-looking statements reminding investors of associated risks. Successful FDA agreement could open a materially larger market by allowing IGALMI to be self-administered outside clinical settings, but approval is still contingent on future FDA review.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) filed a Form 8-K on 15 July 2025 to disclose a patent milestone for its commercial product Igalmi. The U.S. Patent & Trademark Office has allowed U.S. Patent Application No. 18/600,419, which covers administration of a single oromucosal dose of up to 120 mcg dexmedetomidine for treating acute agitation associated with schizophrenia or bipolar disorder in patients exhibiting a QT prolongation of <6 Âµs. Once issued, the patent will be eligible for Orange Book listing and will become the 14th Orange Book-listed patent for Igalmi. The patent carries an expiry date of 12 January 2043, subject to any patent-term adjustment. No financial metrics or other operational updates were included in this filing.

• Form type: 8-K â€� Item 8.01 (Other Events)
• Event date: 15 July 2025
• Key asset: Igalmi (dexmedetomidine oromucosal film)
• IP impact: additional Orange Book protection through 2043, strengthening the product’s U.S. exclusivity position

Willis Lease Finance Corp. (WLFC) � Form 144/A filing reports a proposed insider sale.

• Shares to be sold: 7,295 common shares.
• Estimated market value: $1,058,573.15 (based on information supplied in the filing).
• Broker: Merrill Lynch, 77 Broad Street, Red Bank, NJ 07701.
• Approximate sale date: 06/27/2025 on the NASDAQ.
• Shares outstanding: 6,902,975, so the proposed sale equals roughly 0.11 % of total shares.
• Acquisition details: Shares were acquired on 04/01/2024 through stock compensation.
• Recent prior sales: The seller (identified in the filing as Brian Hole, 30 White Pine Lane, West Hartford, CT 06107) sold 2,893 shares on 05/27/2025 for $386,744.40 and 2,807 shares on 05/23/2025 for $368,973.16, indicating a continuing disposition program.

The filing contains the customary representation that the seller is not aware of undisclosed material adverse information. No other financial or operational data is included.